ZNF224 and B-cell chronic lymphocytic leukemia: Oncogenic features of ZNF224 have also been documented in BRCA [145] and chronic lymphocytic leukemia (CLL) (Figure 4) [146], specifically in terms of increased chemoresistance against camptothecin and fludarabine, respectively.